Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) is expected to be releasing its results before the market opens on Thursday, November 5th. Analysts expect Cartesian Therapeutics to announce earnings of ($1.02) per share and revenue of $0.16 million for the quarter.
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $1.34. On average, analysts expect Cartesian Therapeutics to post ($3.15) EPS for the current fiscal year and ($4.14) EPS for the next fiscal year.
Cartesian Therapeutics Price Performance
RNAC traded up $0.35 during midday trading on Tuesday, reaching $6.69. 8,961 shares of the company’s stock traded hands, compared to its average volume of 192,171. Cartesian Therapeutics has a 52 week low of $5.60 and a 52 week high of $11.00. The firm has a fifty day moving average of $7.66 and a two-hundred day moving average of $7.65. The stock has a market capitalization of $202.49 million, a price-to-earnings ratio of -1.12 and a beta of 0.65.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on RNAC shares. Wedbush reissued an “outperform” rating and set a $38.00 target price on shares of Cartesian Therapeutics in a research note on Tuesday, August 18th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Cartesian Therapeutics in a report on Wednesday, September 30th. Needham & Company LLC reiterated a “buy” rating and issued a $40.00 price target on shares of Cartesian Therapeutics in a report on Tuesday, September 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cartesian Therapeutics in a research report on Wednesday, September 9th. Finally, Zacks Research upgraded shares of Cartesian Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.
Cartesian Therapeutics Company Profile
Cartesian Therapeutics, Inc (NASDAQ: RNAC) is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s platform is designed to program a patient’s own immune cells with messenger RNA, enabling the development of cell therapies that are intended to provide targeted treatment without permanent genetic modification.
Cartesian’s lead product candidate is Descartes-08, an autologous CAR T-cell therapy that targets B-cell maturation antigen (BCMA).
Further Reading
- Five stocks we like better than Cartesian Therapeutics
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
- Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat
- Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?
- Check Point’s Turnaround Could Be Closer Than Investors Think
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
